Follow The Filings

ADCT Adc Therapeutics SA

Health Care, filed as ADC THERAPEUTICS SA (SHS), Equity As of 2026 Q3 so far: 135 of 140 managers we track have filed Quote on Google Finance, opens in a new tab

Bought by 1 manager in 2026 Q3, sold by 1

  • 2 Owners
  • Max 0.6%
  • $5M
  • 1 add 1 reduce

In 2026 Q3 James Silverman added to Adc Therapeutics, while Nathan Fischel trimmed.

Who owns this now

Largest portfolio weights among holders, up to 0.6% (James Silverman, Opaleye Management). Not free-float ownership.

  1. James Silverman Add 0.56%
  2. Nathan Fischel Reduce 0.01%

Who owns ADCT

Sorted by value, long equity only, as of 2026 Q3.

History
James Silverman, Opaleye Management 0.56%, was 0.07% Add +481.5% 4,070,819 $5M History
Nathan Fischel, DAFNA Capital Management 0.01% Reduce −25.9% 57,081 $70K History

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by ADCT's executives, directors and 10% owners in the last 12 months, from their Form 4s

All ADCT insider trades
  • None no insider bought on the open market
  • $19.6M sold by 1 insider outside a trading plan
  • None no planned (10b5-1) sales
  1. Redmile Group, LLC 10% owner, +2 joint filers
    Sale
    $19.6M 5,880,415 shares at $3.34
    Traded Mar 31–Apr 2 Filed Apr 2

Also filed in the last 12 months, not counted as buying or selling: 17 share withholdings for taxes and 16 stock grants.

Congress

No member of Congress reported trading ADCT in the last three years. 1 member listed it in 2025 annual reports.

All Congress trades

SEC filings

Recent issuer filings from EDGAR, 25 shown.

Filed Form Detail Links
424B3 FORM 424B3
SCHEDULE 13G/A —
10-Q
8-K 2.02,9.01
8-K 2.02,7.01,8.01,9.01
SCHEDULE 13G —
8-K 1.01,2.02,3.02,9.01
SCHEDULE 13G —
8-K 2.02,7.01,9.01
10-Q
SCHEDULE 13G —
8-K 5.02
8-K 7.01,8.01,9.01
8-K 7.01,8.01,9.01
8-K 5.07,9.01
8-K 2.02,9.01
10-Q
SCHEDULE 13G/A —
DEF 14A
DEFA14A FORM DEFA14A
424B3 FORM 424B3
SCHEDULE 13G/A —
424B3 FORM 424B3
8-K 2.02,9.01
10-K

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Revenue $69.06M — —
Gross profit * $66.53M — —
Gross margin * 96.3% — —
Net income -$240.05M -$157.85M -$142.62M
Net margin * -347.6% — —

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $336.29M $307.39M $306.34M
Total non-current assets * $18.49M $14.59M $16.82M
Total assets $354.78M $321.98M $323.15M
Total current liabilities $67.67M $80.47M $70.16M
Total non-current liabilities * $435.36M $444.15M $438.82M
Total equity -$148.25M -$202.64M -$185.83M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$118.69M -$123.84M -$141.17M
Cash from investing -$3.22M -$0.867M $0.395M
Cash from financing $73.88M $97.05M $150.94M
Net change in cash * -$48.03M -$27.65M $10.17M

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

More on the shelf